2Cryerp E,Davis N,Shamoon H.Hypoglyeenia in diabetes[J].Diabetes Care,2003,26(6):1902-1912. 被引量：1
3HERMAN GA,BERGMAN A,STEVENS C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2006,91 (11):4612-4619. 被引量：1
4BERGMAN AJ,STEVENS C,ZHOU Y,et al.Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin,a dipeptidyl peptidase-Ⅳ inhibitor:a double-blind,randomized,placebo-controlled study in healthy male volunteers[J].Clin Ther,2006,28(1):55 -72. 被引量：1
5HERMAN GA,BERGMAN A,LIU F,et al.Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitaglipin in middle-aged obese subjects[J].J Clin Pharmacol,2006,46(8):876 -886. 被引量：1
6HERMAN GA,STEVENS C,VAN DYCK K,et al.Pharmacokinetics and pharmacodynamics of sitagliptin,an inhibitor of dipeptidyl peptidase Ⅳ,in healthy subjects:results from two randomized,double-blind,placebo-controlled studies with single oral doses[J].Clin Pharmacol Ther,2005,78(6):675 -688. 被引量：1
7VINCENT SH,REED JR,BERGMAN AJ,et al.Metabolism and excretion of the DPP-4 inhibitor[14C] sitagliptin in humans[J].Drug Metab Dispos,2007,35(4):533 -538. 被引量：1
8RAZ I,HANEFELD M,XU L,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitsgliptin as monotherapy in patients with type 2 diabetes mellitus[J].Diabetologia,2006,49(11):2564 -2571. 被引量：1
9ASCHNER P,KIPNES MS,LUNCEFORD JK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes[J].Diabetes Care,2006,29(12):2632 -2637. 被引量：1
10SCOTT R,WU M,SCANCHEZ M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes[J].Int J Clin Pract,2007,61(1):171 -180. 被引量：1
